Laura Huppert

Dr. Laura Huppert, an academic medical oncologist at UCLA, joins to unpack groundbreaking findings from the SABCS 2025 conference on early-stage hormone receptor-positive breast cancer. She delves into the ALTTO study, highlighting the advantage of aromatase inhibitors over tamoxifen. The discussion then moves to the lidERA study, spotlighting the potential of giredestrant in improving invasive disease-free survival. Finally, insights from the NATALEE trial showcase the enduring benefits of ribociclib across various patient subgroups, reshaping treatment strategies.